Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Drug

Jiangsu Hengrui Receives NMPA Approval to Begin Clinical Trials for New Anticancer Biologic

Fineline Cube Jun 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Shenzhen Light and Biotechnology Partners with Shenzhen Increcare Biotech in IVD Sector

Fineline Cube Jun 5, 2024

Shenzhen Light and Biotechnology Co., Ltd, a company based in China, has entered into a...

Company Drug

AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA

Fineline Cube Jun 5, 2024

AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the...

Company Deals

OBiO Technology Partners with Shenzhen Innovation Immunotechnology for TCR-T Cell Therapy Development

Fineline Cube Jun 5, 2024

OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in...

Company Drug

Olymvax Bio Receives Ethical Approval for Oral Helicobacter pylori Vaccine Trial in Australia

Fineline Cube Jun 5, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...

Company Drug

Sanofi Receives NMPA Approval for Phase III Clinical Trial of RSV Vaccine SP0125

Fineline Cube Jun 5, 2024

Sanofi (EPA: SAN), a major French multinational pharmaceutical company, has announced that it has received...

Company Deals Medical Device

BOE-Backed Genewise Bio Secures RMB 100 Million in Series A Financing for Molecular Diagnostics

Fineline Cube Jun 5, 2024

Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB...

Company Drug

Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA

Fineline Cube Jun 5, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that...

Hospital Policy / Regulatory

China’s NHC Mandates Urban Hospitals to Aid County-Level Medical Institutions

Fineline Cube Jun 5, 2024

The National Health Commission (NHC) has issued a notification aimed at further promoting the allocation...

Company Drug

Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial

Fineline Cube Jun 5, 2024

Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy...

Company Drug

AstraZeneca’s Tagrisso Achieves Milestone Progression-Free Survival in Late-Stage Lung Cancer Study

Fineline Cube Jun 5, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has announced preliminary results from...

Company Drug

MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study

Fineline Cube Jun 5, 2024

MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...

Company Deals

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Fineline Cube Jun 5, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary,...

Company Deals

Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases

Fineline Cube Jun 5, 2024

Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP

Fineline Cube Jun 4, 2024

Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...

Company Medical Device

Zylox-Tonbridge Medical Technology Earns NMPA Approval for First Vascular Stapler in China

Fineline Cube Jun 4, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Deals Drug

Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody

Fineline Cube Jun 4, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...

Company Drug

Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs

Fineline Cube Jun 4, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...

Company

China Meheco Group Appoints Yang Guang as Chairman and Legal Representative

Fineline Cube Jun 4, 2024

China Meheco Group Co., Ltd (SHA: 600056) has announced the appointment of Yang Guang to...

Company Drug

Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China

Fineline Cube Jun 4, 2024

Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...

Posts pagination

1 … 391 392 393 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.